-
-
-
Dietary Intervention for Fatty Liver Disease: Fat or Carbohydrate Restriction?; Motivational Interviewing to Enhance Weight Control in Diabetic Women; One-stop Shopping for Osteoporosis Treatment; Post-stroke prevention of venous thromboembolism; Chronic Kidney Disease: Treatment Modality and Quality of Life; Hepatitis C and Risk for Lymphoma
-
Botulinum Toxin for Treatment of Hyperhidrosis; A Fish Story; Diabetes Control: It's More Than Just A1c Control; MI: Try to have it Monday Thru Friday; Can MRI Provide Better Clarity About Contralateral Breast Cancer?; Dapsone Gel 5% for Acne
-
Treatment of Periodontitis and Endothelial Function; Does Cost-Conscious Prescribing Hamper Clinical Outcomes?; Induction of Macrolide-Resistant Streptococci; Pulse Pressure and Risk of New-Onset Atrial Fibrillation; Challenges to the Stages of Grief Theory; EKG Abnormalities in Asymptomatic Women: Association with CV Events
-
Predicting Stroke Risk after TIA; Which is the Better Study in Acute Stroke: CT or MRI?; Comparison of a DPP-4 and TZD for Monotherapy in Type 2 Diabetes; Hypertension Treatment in "Real Life": How are We Doing?; Can We Prevent Recurrences of Diabetic Foot Ulcers?; Contact Sensitizers Are Surprisingly Common in Chronic Urticaria
-
Alendronate: How Much of a Good Thing?; Early Localized Prostate Cancer: Does Intervention Make a Difference?; CV Biomarkers: The More Is Not Always the Merrier; BNP: Not Just for Heart Failure; Like Everything Else, The Brain is Use It or Lose It; High Vitamin D Levels are Associated with Reduced Risk of MS
-
Lumbar Disk Herniation: Is Surgical Treatment Superior to Conservative Management?; Rimonabant: An Answer to Overweight in Diabetes?; Renin Inhibitors: A new Class of Antihypertensive Agents; Is There a Link between Coffee and Diabetes?; Is it Time to Start Screening for Lung Cancer?; Can Ramipril Prevent Progression from Pre-Diabetes to Diabetes?
-
Hip fractures (hip) occur 2-4 times more commonly in persons who have sustained a stroke than an age-matched population.
-
Although we have recently enjoyed the FDA approval of two agents for treatment of diabetic peripheral neuropathic pain (duloxetine [Cymbalta], pregabalin [Lyrica]), as yet we have no treatment for diabetic peripheral neuropathy (DPN) itself.
